AI Improves Treatment in Women with Heart Attacks

Heart attacks are one of the leading causes of death worldwide, and women who suffer a heart attack have a higher mortality rate than men. This has been a matter of concern to cardiologists for decades and has led to controversy in the medical field about the causes and effects of possible gaps in treatment. The problem starts with the symptoms: unlike men, who usually experience chest pain with radiation to the left arm, a heart attack in women often manifests as abdominal pain radiating to the back or as nausea and vomiting. These symptoms are unfortunately often misinterpreted by the patients and healthcare personnel - with disastrous consequences.

Risk profile and clinical picture is different in women

An international research team led by Thomas F. Lüscher, professor at the Center for Molecular Cardiology at the University of Zurich (UZH), has now investigated the role of biological sex in heart attacks in more detail. "Indeed, there are notable differences in the disease phenotype observed in females and males. Our study shows that women and men differ significantly in their risk factor profile at hospital admission,” says Lüscher. When age differences at admission and existing risk factors such as hypertension and diabetes are disregarded, female heart-attack patients have higher mortality than male patients. “However, when these differences are taken into account statistically, women and men have similar mortality," the cardiologist adds.

Current risk models favor under-treatment of female patients

In their study, published in the prestigious journal The Lancet, researchers from Switzerland and the United Kingdom analyzed data from 420,781 patients across Europe who had suffered the most common type of heart attack. "The study shows that established risk models which guide current patient management are less accurate in females and favor the undertreatment of female patients," says first author Florian A. Wenzl of the Center for Molecular Medicine at UZH. "Using a machine learning algorithm and the largest datasets in Europe we were able to develop a novel artificial- intelligence-based risk score which accounts for sex-related differences in the baseline risk profile and improves the prediction of mortality in both sexes," Wenzl says.

AI-based risk profiling improves individualized care

Many researchers and biotech companies agree that artificial intelligence and Big Data analytics are the next step on the road to personalized patient care. "Our study heralds the era of artificial intelligence in the treatment of heart attacks," says Wenzl. Modern computer algorithms can learn from large data sets to make accurate predictions about the prognosis of individual patients - the key to individualized treatments.

Thomas F. Lüscher and his team see huge potential in the application of artificial intelligence for the management of heart disease both in male and female patients. "I hope the implementation of this novel score in treatment algorithms will refine current treatment strategies, reduce sex inequalities, and eventually improve the survival of patients with heart attacks - both male and female," says Lüscher.

Florian A Wenzl, Simon Kraler, Gareth Ambler, Clive Weston, Sereina A Herzog, Lorenz Räber, Olivier Muller, Giovanni G Camici, Marco Roffi, Hans Rickli, Keith A A Fox, Mark de Belder, Dragana Radovanovic, John Deanfield, Thomas F Lüscher.
Sex-specific evaluation and redevelopment of the GRACE score in non-ST-segment elevation acute coronary syndromes in populations from the UK and Switzerland: a multinational analysis with external cohort validation.
The Lancet, 2022. doi: 10.1016/S0140-6736(22)01483-0

Most Popular Now

The Future of Medicine is Data

At the 2023 Annual J.P. Morgan Healthcare Conference, Owkin Co-founder and CEO Thomas Clozel, MD will outline how data is the future of medicine - from the development of new...

Study Surveys Landscape of Apps Built on…

A study led by Regenstrief Institute Research Scientist Titus K. Schleyer, DMD, PhD, is among the first to survey the current landscape of FHIR® apps, providing a snapshot of how...

New Computer Program 'Learns' to Identif…

Genetic mutations cause hundreds of unsolved and untreatable disorders. Among them, DNA mutations in a small percentage of cells, called mosaic mutations, are extremely difficult to detect because they exist...

Applications Open for SpinLab Accelerato…

The start-up accelerator supports entrepreneurial and innovative teams that want to grow sustainably and successfully scale their business model. With a strong hands-on mentality and a lot of passion, the...

Bayer to Accelerate Drug Discovery with …

Bayer AG and Google Cloud today announced a collaboration to drive early drug discovery that will apply Google Cloud's Tensor Processing Units (TPUs), which are custom-developed accelerators designed to run...

Allscripts Announces Corporate Name Chan…

Allscripts Healthcare Solutions, Inc. announced that, effective January 1, 2023, it has changed its name to Veradigm Inc. (NASDAQ: MDRX). Allscripts had been transitioning its solutions to the Veradigm brand...

220M€ Investment in Testing and Experime…

To make the EU the place where AI excellence thrives from the lab to the market, the European Union is setting up world-class Testing and Experimentation Facilities (TEFs) for AI. Together...

AI Tool Developed to Predict Risk of Lun…

Lung cancer is the leading cause of cancer death in the United States and around the world. Low-dose chest computed tomography (LDCT) is recommended to screen people between 50 and...

Artificial Nerve Cells - Almost Like Bio…

Researchers at Linköping University (LiU), Sweden, have created an artificial organic neuron that closely mimics the characteristics of biological nerve cells. This artificial neuron can stimulate natural nerves, making it...

Bayer Acquires Blackford Analysis Ltd. B…

Bayer announced the acquisition of the global strategic imaging AI platform and solutions provider Blackford Analysis Ltd. The acquisition is part of Bayer's strategy to drive innovation in radiology, including...

For Shared Decision-Making, Telemedicine…

Telemedicine may be just as effective as in-person visits when it comes to shared decision-making and communication for patients undergoing a first-time surgery consultation, according to a study published as...

Veradigm Announces Strategic Investment …

Veradigm Inc. (NASDAQ: MDRX), formerly Allscripts Healthcare Solutions, Inc., announced an investment in Holmusk, a global behavioral health real-world evidence and data analytics company, as part of Holmusk's $45 million...